Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dopamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Piramal Critical Care
Deal Size : Inapplicable
Deal Type : Inapplicable
BrePco Biopharma and Piramal Critical Care Announce MHRA Approval for Neoatricon in UK
Details : Neoatricon (dopamine hydrochloride) is a Beta-1 adrenergic receptor stimulator, small molecule drug candidate, which is indicated for the treatment of hypotension.
Product Name : Neoatricon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2025
Lead Product(s) : Dopamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Piramal Critical Care
Deal Size : Inapplicable
Deal Type : Inapplicable